AbbVie Inc. (ABBV) shareholders
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/3087% above fair value
$295.03+0.58 (+0.20%)
Close on Nov 13, 2026Market cap $521.35BP/E 83.3Yield 2.25%
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
75.6%
1.34B of 1.77B shares
Institutional holders
4,210
286 new, 111 sold out
Net institutional buying
43M
In Q2 2026
Insider trades, 12 months
0 buys · 7 sales
Net sold $30.85M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 143,180,060 | 8.10% | 13G (passive) amendment | Dec 31, 2023 |
| Vanguard Capital Management | 132,924,058 | 7.51% | 13G (passive) | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ABBV | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 149,488,412 | 8.46% | $37.62B | −1,209,713 | 0.56% |
| Vanguard Capital Management LLC | 115,396,098 | 6.53% | $29.04B | +515,774 | 0.62% |
| State Street Corp | 82,596,748 | 4.67% | $20.78B | +1,379,232 | 0.62% |
| Vanguard Portfolio Management LLC | 48,477,996 | 2.74% | $12.20B | −1,045,082 | 0.55% |
| JPMorgan Chase & Co | 47,862,796 | 2.71% | $12.17B | −8,878,895 | 0.67% |
| Geode Capital Management, LLC | 46,998,433 | 2.66% | $11.81B | +260,852 | 0.63% |
| Morgan Stanley | 38,901,001 | 2.20% | $9.79B | +884,227 | 0.52% |
| Capital Research Global Investors | 30,101,551 | 1.70% | $7.57B | −1,153,235 | 1.06% |
| Norges Bank | 25,554,538 | 1.45% | $6.43B | New | 0.64% |
| Bank Of America Corp /De/ | 21,237,764 | 1.20% | $5.34B | −2,699,179 | 0.34% |
| FMR LLC | 20,773,786 | 1.18% | $5.23B | −988,917 | 0.23% |
| Northern Trust Corp | 20,558,447 | 1.16% | $5.17B | −652,935 | 0.60% |
| Franklin Resources Inc | 19,925,232 | 1.13% | $5.01B | +5,373,163 | 1.09% |
| Capital World Investors | 19,178,966 | 1.09% | $4.83B | +3,337,599 | 0.57% |
| Goldman Sachs Group Inc | 16,291,630 | 0.92% | $4.10B | +1,146,351 | 0.36% |
| Capital International Investors | 15,638,631 | 0.88% | $3.94B | +1,219,638 | 0.81% |
| Price T Rowe Associates Inc /Md/ | 14,749,069 | 0.83% | $3.71B | +1,745,080 | 0.37% |
| UBS Asset Management Americas Inc | 14,267,697 | 0.81% | $3.59B | +106,091 | 0.65% |
| Charles Schwab Investment Management Inc | 12,914,230 | 0.73% | $3.25B | −53,168 | 0.43% |
| Bank of New York Mellon Corp | 12,853,368 | 0.73% | $3.23B | −424,793 | 0.53% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 4,210 | 1.34B | 75.6% | 286 / 1921 | 1534 / 111 | 99M | 55M |
| Q1 2026 | 4,104 | 1.30B | 73.7% | 192 / 1731 | 1717 / 182 | 258M | 97M |
| Q4 2025 | 4,159 | 1.33B | 75.0% | 458 / 1602 | 1647 / 125 | 98M | 98M |
| Q3 2025 | 3,915 | 1.33B | 75.2% | 295 / 1662 | 1474 / 101 | 102M | 72M |
| Q2 2025 | 3,787 | 1.30B | 73.7% | 182 / 1709 | 1470 / 167 | 80M | 65M |
| Q1 2025 | 3,826 | 1.29B | 73.0% | 266 / 1491 | 1630 / 125 | 69M | 55M |
| Q4 2024 | 3,749 | 1.29B | 72.8% | 440 / 1501 | 1415 / 131 | 85M | 113M |
| Q3 2024 | 3,506 | 1.32B | 74.9% | 244 / 1424 | 1398 / 71 | 177M | 39M |
| Q2 2024 | 3,371 | 1.32B | 74.8% | 154 / 1474 | 1316 / 125 | 57M | 111M |
| Q1 2024 | 3,385 | 1.38B | 78.1% | 222 / 1337 | 1493 / 116 | 98M | 45M |
| Q4 2023 | 3,327 | 1.33B | 75.3% | 367 / 1177 | 1423 / 98 | 137M | 35M |
| Q3 2023 | 3,114 | 1.23B | 69.8% | 176 / 1278 | 1284 / 106 | 42M | 36M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
1,381 funds held ABBV in Q2 2026, 53% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of ABBV | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 56,090,167 | 3.17% | $14.11B | 0.61% | Jun 30, 2026 |
| Vanguard 500 Index Fund | 45,784,614 | 2.59% | $11.52B | 0.69% | Jun 30, 2026 |
| iShares Core S&P 500 ETF | 24,302,850 | 1.38% | $6.12B | 0.69% | Jun 30, 2026 |
| Fidelity 500 Index Fund | 22,617,268 | 1.28% | $4.92B | 0.59% | May 31, 2026 |
| Vanguard Value Index Fund | 16,815,764 | 0.95% | $4.23B | 1.66% | Jun 30, 2026 |
| State Street(R) Health Care Select Sector SPDR(R) ETF | 12,481,854 | 0.71% | $3.14B | 7.74% | Jun 30, 2026 |
| American Mutual Fund | 11,145,520 | 0.63% | $2.80B | 2.37% | Jul 31, 2026 |
| Capital Income Builder | 10,055,634 | 0.57% | $2.52B | 1.93% | Jul 31, 2026 |
| Vanguard Dividend Appreciation Index Fund | 9,996,424 | 0.57% | $2.51B | 1.92% | Jul 31, 2026 |
| Washington Mutual Investors Fund | 9,627,943 | 0.54% | $2.42B | 1.11% | Jul 31, 2026 |
| Vanguard Institutional Index Fund | 9,591,323 | 0.54% | $2.41B | 0.69% | Jun 30, 2026 |
| Income Fund of America | 8,590,236 | 0.49% | $2.16B | 1.45% | Jul 31, 2026 |
| Vanguard High Dividend Yield Index Fund | 7,128,692 | 0.40% | $1.79B | 1.80% | Jul 31, 2026 |
| Investment Co of America | 6,525,474 | 0.37% | $1.64B | 0.89% | Jun 30, 2026 |
| Fidelity SAI U.S. Quality Index Fund | 5,530,685 | 0.31% | $1.39B | 3.88% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Robert A. Michael | CHAIRMAN OF THE BOARD AND CEO, Director | 178,737 | 0.01% | Mar 3, 2026 |
| Jeffrey Ryan Stewart | EVP, CHIEF COMMERCIAL OFFICER | 81,059 | 0.00% | Nov 12, 2026 |
| Nicholas Donoghoe | EVP, CHIEF BUS/STRAT OFFICER | 74,430 | 0.00% | Aug 18, 2026 |
| David Ryan Purdue | SVP, Controller | 9,011 | 0.00% | Mar 11, 2026 |
| Demetris D. Crum | EVP, CHIEF HR OFFICER | 7,914 | 0.00% | Mar 6, 2026 |
| Roopal Thakkar | EVP, R&D and CSO | 55,374 | 0.00% | Mar 3, 2026 |
| Azita Saleki-Gerhardt | EVP, CHIEF OPERATIONS OFFICER | 204,373 | 0.01% | Mar 3, 2026 |
| Perry C. Siatis | EVP, GC AND SECRETARY | 17,510 | 0.00% | Mar 3, 2026 |
| Scott T. Reents | EVP, CHIEF FINANCIAL OFFICER | 38,777 | 0.00% | Mar 3, 2026 |
| Inc. AbbVie | EVP, Chief HR Officer | 7,048 | 0.00% | Jul 11, 2025 |
| Timothy J. Richmond | EVP, CHIEF HR OFFICER | 6,130 | 0.00% | Mar 4, 2025 |
| Kevin K. Buckbee | SVP, CONTROLLER | 7,797 | 0.00% | Mar 4, 2025 |
| John Carethers | Director | – | – | Oct 23, 2026 |
| Susan E. Quaggin | Director | 3,643 | 0.00% | Oct 2, 2026 |
| Edward J. Rapp | Director | 56,352 | 0.00% | Oct 2, 2026 |
| Frederick H. Waddell | Director | 30,076 | 0.00% | May 12, 2026 |
| Jennifer L. Davis | Director | 3,643 | 0.00% | May 12, 2026 |
| Thomas J. Falk | Director | 5,321 | 0.00% | May 12, 2026 |
| Brett J. Hart | Director | 20,590 | 0.00% | May 12, 2026 |
| Rebecca B. Roberts | Director | 14,846 | 0.00% | May 12, 2026 |
| William H.L. Burnside | Director | 28,076 | 0.00% | May 12, 2026 |
| Thomas C. Freyman | Director | 133,810 | 0.01% | May 12, 2026 |
| Melody B. Meyer | Director | 17,616 | 0.00% | May 12, 2026 |
| Roxanne S. Austin | Director | 39,576 | 0.00% | May 12, 2026 |
| Robert J. Alpern | Director | 35,646 | 0.00% | Apr 2, 2026 |
| Glenn F. Tilton | Director | 51,914 | 0.00% | May 13, 2025 |
| Richard A. Gonzalez | Director | 415,894 | 0.02% | Apr 2, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Jeffrey Ryan Stewart EVP, CHIEF COMMERCIAL OFFICER | Nov 12, 2026 | Gift | −3,450 | – | – | 79,721 |
| Jeffrey Ryan Stewart EVP, CHIEF COMMERCIAL OFFICER | Nov 9, 2026 | Sale | −40,619 | $293.60 | $11.93M | 83,171 |
| Jeffrey Ryan Stewart EVP, CHIEF COMMERCIAL OFFICER | Nov 9, 2026 | Option exercise | +24,549 | $93.50 | $2.30M | 123,790 |
| Jeffrey Ryan Stewart EVP, CHIEF COMMERCIAL OFFICER | Nov 9, 2026 | Option exercise | +16,070 | $114.36 | $1.84M | 99,241 |
| Nicholas Donoghoe EVP, CHIEF BUS/STRAT OFFICER | Aug 14, 2026 | Sale | −32,710 | $250.00 | $8.18M | 74,430 |
| Nicholas Donoghoe EVP, CHIEF BUS/STRAT OFFICER | Aug 14, 2026 | Option exercise | +32,710 | $79.02 | $2.58M | 107,140 |
| William H.L. Burnside Director | May 8, 2026 | Award | +1,118 | – | – | 28,076 |
| Jennifer L. Davis Director | May 8, 2026 | Award | +1,118 | – | – | 3,643 |
| Brett J. Hart Director | May 8, 2026 | Award | +1,118 | – | – | 20,590 |
| Roxanne S. Austin Director | May 8, 2026 | Award | +1,118 | – | – | 39,576 |
| Melody B. Meyer Director | May 8, 2026 | Award | +1,118 | – | – | 17,616 |
| Frederick H. Waddell Director | May 8, 2026 | Award | +1,118 | – | – | 30,076 |
| Rebecca B. Roberts Director | May 8, 2026 | Award | +1,118 | – | – | 14,846 |
| Thomas J. Falk Director | May 8, 2026 | Award | +1,118 | – | – | 2,321 |
| Thomas C. Freyman Director | May 8, 2026 | Award | +1,118 | – | – | 127,869 |
| Susan E. Quaggin Director | May 8, 2026 | Award | +1,118 | – | – | 3,643 |
| Edward J. Rapp Director | May 8, 2026 | Award | +1,118 | – | – | 45,964 |
| David Ryan Purdue SVP, Controller | Mar 4, 2026 | Sale | −5,230 | $233.56 | $1.22M | 2,654 |
| Perry C. Siatis EVP, GC AND SECRETARY | Mar 2, 2026 | Sale(10b5-1 plan) | −5,777 | $233.51 | $1.35M | 17,510 |
| Perry C. Siatis EVP, GC AND SECRETARY | Mar 2, 2026 | Sale(10b5-1 plan) | −2,600 | $235.26 | $611.68K | 4,619 |
| Perry C. Siatis EVP, GC AND SECRETARY | Mar 2, 2026 | Sale(10b5-1 plan) | −10,291 | $234.66 | $2.41M | 7,219 |
| David Ryan Purdue SVP, Controller | Feb 27, 2026 | Tax withholding | −2,108 | $232.08 | $489.22K | 8,468 |
| Demetris D. Crum EVP, CHIEF HR OFFICER | Feb 27, 2026 | Tax withholding | −1,594 | $232.08 | $369.94K | 7,914 |
| Nicholas Donoghoe EVP, CHIEF BUS/STRAT OFFICER | Feb 27, 2026 | Tax withholding | −12,874 | $232.08 | $2.99M | 74,430 |
| Roopal Thakkar EVP, R&D and CSO | Feb 27, 2026 | Tax withholding | −8,037 | $232.08 | $1.87M | 52,376 |
| Perry C. Siatis EVP, GC AND SECRETARY | Feb 27, 2026 | Tax withholding | −14,850 | $232.08 | $3.45M | 23,287 |
| Jeffrey Ryan Stewart EVP, CHIEF COMMERCIAL OFFICER | Feb 27, 2026 | Tax withholding | −23,812 | $232.08 | $5.53M | 83,171 |
| Scott T. Reents EVP, CHIEF FINANCIAL OFFICER | Feb 27, 2026 | Tax withholding | −21,638 | $232.08 | $5.02M | 38,777 |
| Robert A. Michael CHAIRMAN OF THE BOARD AND CEO, Director | Feb 27, 2026 | Tax withholding | −36,523 | $232.08 | $8.48M | 178,737 |
| David Ryan Purdue SVP, Controller | Feb 27, 2026 | Tax withholding | −2,692 | $232.08 | $624.76K | 7,884 |
| Azita Saleki-Gerhardt EVP, CHIEF OPERATIONS OFFICER | Feb 27, 2026 | Tax withholding | −16,309 | $232.08 | $3.78M | 197,794 |
| Perry C. Siatis EVP, GC AND SECRETARY | Feb 25, 2026 | Sale(10b5-1 plan) | −22,381 | $230.00 | $5.15M | 38,137 |
| Perry C. Siatis EVP, GC AND SECRETARY | Feb 25, 2026 | Option exercise | +7,775 | $175.28 | $1.36M | 53,226 |
| Perry C. Siatis EVP, GC AND SECRETARY | Feb 25, 2026 | Option exercise | +7,314 | $149.62 | $1.09M | 45,451 |
| Perry C. Siatis EVP, GC AND SECRETARY | Feb 25, 2026 | Option exercise | +7,292 | $192.86 | $1.41M | 60,518 |
| Perry C. Siatis EVP, GC AND SECRETARY | Feb 18, 2026 | Award | +5,792 | – | – | 26,701 |
| Perry C. Siatis EVP, GC AND SECRETARY | Feb 18, 2026 | Award | +5,628 | – | – | 32,329 |
| Perry C. Siatis EVP, GC AND SECRETARY | Feb 18, 2026 | Award | +16,290 | – | – | 20,909 |
| Perry C. Siatis EVP, GC AND SECRETARY | Feb 18, 2026 | Award | +5,808 | – | – | 38,137 |
| Demetris D. Crum EVP, CHIEF HR OFFICER | Feb 18, 2026 | Award | +1,216 | – | – | 8,264 |
| Demetris D. Crum EVP, CHIEF HR OFFICER | Feb 18, 2026 | Award | +1,244 | – | – | 9,508 |
| David Ryan Purdue SVP, Controller | Feb 18, 2026 | Award | +890 | – | – | 7,900 |
| David Ryan Purdue SVP, Controller | Feb 18, 2026 | Award | +2,505 | – | – | 7,010 |
| David Ryan Purdue SVP, Controller | Feb 18, 2026 | Award | +1,384 | – | – | 10,576 |
| David Ryan Purdue SVP, Controller | Feb 18, 2026 | Award | +1,292 | – | – | 9,192 |
| Robert A. Michael CHIEF EXECUTIVE OFFICER, Director | Feb 18, 2026 | Award | +22,124 | – | – | 215,260 |
| Robert A. Michael CHIEF EXECUTIVE OFFICER, Director | Feb 18, 2026 | Award | +33,833 | – | – | 166,654 |
| Robert A. Michael CHIEF EXECUTIVE OFFICER, Director | Feb 18, 2026 | Award | +12,030 | – | – | 178,684 |
| Robert A. Michael CHIEF EXECUTIVE OFFICER, Director | Feb 18, 2026 | Award | +14,452 | – | – | 193,136 |
| Nicholas Donoghoe EVP, CHIEF BUS/STRAT OFFICER | Feb 18, 2026 | Award | +5,172 | – | – | 81,082 |
| Nicholas Donoghoe EVP, CHIEF BUS/STRAT OFFICER | Feb 18, 2026 | Award | +4,632 | – | – | 75,910 |
| Nicholas Donoghoe EVP, CHIEF BUS/STRAT OFFICER | Feb 18, 2026 | Award | +6,222 | – | – | 87,304 |
| Nicholas Donoghoe EVP, CHIEF BUS/STRAT OFFICER | Feb 18, 2026 | Award | +13,031 | – | – | 71,278 |
| Jeffrey Ryan Stewart EVP, CHIEF COMMERCIAL OFFICER | Feb 18, 2026 | Award | +26,063 | – | – | 79,297 |
| Jeffrey Ryan Stewart EVP, CHIEF COMMERCIAL OFFICER | Feb 18, 2026 | Award | +8,988 | – | – | 106,983 |
| Jeffrey Ryan Stewart EVP, CHIEF COMMERCIAL OFFICER | Feb 18, 2026 | Award | +9,432 | – | – | 97,995 |
| Jeffrey Ryan Stewart EVP, CHIEF COMMERCIAL OFFICER | Feb 18, 2026 | Award | +9,266 | – | – | 88,563 |
| Azita Saleki-Gerhardt EVP, CHIEF OPERATIONS OFFICER | Feb 18, 2026 | Award | +6,638 | – | – | 214,103 |
| Azita Saleki-Gerhardt EVP, CHIEF OPERATIONS OFFICER | Feb 18, 2026 | Award | +7,074 | – | – | 207,465 |
| Azita Saleki-Gerhardt EVP, CHIEF OPERATIONS OFFICER | Feb 18, 2026 | Award | +17,041 | – | – | 194,333 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
0.90%
16M shares short
Days to cover
3.3
At 5M shares a day
Change since last report
+1.5%
From 16M shares
Short volume, 20 days
29.0%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of AbbVie's stock actually held short. Settlement fails (shares not delivered on time) peaked at 99,862 shares on Sep 25, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Jeffrey Ryan Stewart Officer | Nov 9, 2026 | 40,619 | $11.93M | Nov 9, 2026 | Stock Option Exercise |
| Nicholas Donoghoe Officer | Aug 14, 2026 | 32,710 | $8.18M | Aug 14, 2026 | Stock Option Exercise |
| Robert J. Alpern Director | May 26, 2026 | 13,000 | $2.78M | May 26, 2026 | Restricted Stock |
| David Ryan Purdue Officer | Mar 6, 2026 | 5,230 | $1.22M | Mar 4, 2026 | Restricted Stock |
| Perry C. Siatis Officer | Mar 2, 2026 | 18,668 | $4.38M | Mar 2, 2026 | Performance Shares |
| Perry C. Siatis Officer | Feb 25, 2026 | 22,381 | $5.15M | Feb 25, 2026 | Stock Option Exercise |
| Richard A. Gonzalez Former Director | Aug 22, 2025 | 62,755 | $13.23M | Aug 22, 2025 | Stock Option Exercise |
| Richard A. Gonzalez Former Director | Aug 21, 2025 | 90,000 | $18.99M | Aug 21, 2025 | Stock Option Exercise |
| Azita Saleki-Gerhardt Officer | Aug 12, 2025 | 42,370 | $8.41M | Aug 12, 2025 | Stock Option Exercise |
| Richard A. Gonzalez Former Director | Aug 8, 2025 | 188,220 | $38.08M | Aug 1, 2025 | Restricted Stock |
| Nicholas Donoghoe Officer | Aug 5, 2025 | 13,299 | $2.64M | Aug 5, 2025 | Dividend Reinvestment Shares |
| Jeffrey Ryan Stewart Officer | Mar 31, 2025 | 58,832 | $12.36M | Mar 31, 2025 | RESTRICTED STOCK |
| Scott T. Reents Officer | Mar 14, 2025 | 17,644 | $3.75M | Mar 14, 2025 | RESTRICTED STOCK |
| Richard A. Gonzalez Officer | Mar 3, 2025 | 6,168 | $1.30M | Mar 3, 2025 | PERFORMANCE SHARES |
| Perry C. Siatis Officer | Mar 3, 2025 | 18,008 | $3.78M | Mar 3, 2025 | Stock Option Exercise |
See a number that looks wrong?